Tuesday, May 27, 2008

Amgen Announces Webcast to Discuss Results of denosumab Phase 3 Head-to-Head Study versus alendronate at the Upcoming European Symposium on Calcified Tissues Conference

THOUSAND OAKS, Calif. – May 27, 2008 – Amgen (NASDAQ:AMGN) today announced that it will hold a conference call on Wednesday, May 28, 2008, beginning at 8 a.m. Eastern Time to discuss the results of the denosumab Phase 3 head-to-head study versus alendronate (the "141" study) at the upcoming European Symposium on Calcified Tissues (ECTS) Conference in Barcelona, Spain. Speakers will include the principal study investigator, Jacques P. Brown, M.D., Head, Division of Rheumatology, Le Centre hospitalier universitaire de Quebec, and Catherine Stehman-Breen, M.D., Amgen’s vice president, Global Development - Bone Therapeutic Area.

Read the rest of this entry

Posted in Press Releases

Thursday, May 22, 2008

Amgen Posts Medical Education and Foundation Grants and Donations as Part of the Company's 'Clearly Amgen' Initiative

THOUSAND OAKS, Calif. – May 22, 2008 – Amgen (NASDAQ: AMGN) today posted to the company’s Web site grants and donations made by the Amgen Medical Education department (AmgenMED) and the Amgen Foundation. The posting is the latest element of Clearly Amgen, a section of the Company’s Web site designed to provide clear and easy access to Amgen’s policies and practices. Grants, donations and charitable contributions will be updated quarterly along with a brief description of each program or project.

Read the rest of this entry

Posted in Press Releases

Monday, May 19, 2008

Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition Study

Patients Transitioned from Alendronate to Denosumab Therapy Achieved Superior Gains in Bone Mineral Density Versus Those Continuing on Alendronate Therapy

THOUSAND OAKS, Calif. – May 19, 2008 – Amgen (NASDAQ: AMGN) today announced findings from a head-to-head, double-blind trial comparing the effects of denosumab in post-menopausal women with low bone mass transitioned from weekly alendronate (FOSAMAX(R)) versus continued alendronate therapy on bone mineral density (BMD). The study demonstrated superior results for the primary and all secondary endpoints.

Read the rest of this entry

Posted in Press Releases

Thursday, May 15, 2008

Amgen Highlights Data to Be Presented at ASCO

New Data from Denosumab, Vectibix(R) and Mid-Stage Pipeline Demonstrate Progress of Oncology Portfolio

THOUSAND OAKS, Calif. – May 15, 2008 – Amgen (NASDAQ:AMGN) today announced it will present new data from the Company’s oncology portfolio on both approved and investigational cancer therapies at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting that will be held in Chicago from May 30 to June 3, 2008.

Read the rest of this entry

Posted in Press Releases

Tuesday, May 13, 2008

Amgen VP of Investor Relations Arvind Sood to Present at the Baird Growth Stock Conference

THOUSAND OAKS, Calif. – May 13, 2008 – Amgen (NASDAQ:AMGN) Vice President of Investor Relations Arvind Sood will present at the RW Baird Growth Stock Conference on Wednesday, May 14, 2008 beginning at 8:55 a.m. Central Time. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, http://www.amgen.com, under Investors.

Read the rest of this entry

Posted in Press Releases